SciFi Futures
← Capabilities
Biotech & Medicine/Integrated system

Rapid vaccine and therapeutic platforms

Going from a pathogen sequence to a distributed vaccine or antibody in weeks rather than years.

State of the art

2020 mRNA vaccine development from sequence to clinical dosing in 65 days; the 100 Days Mission sets the current target; designed-protein antigens and binders from computational pipelines are now in clinical use.

What’s blocking it
  • Manufacturing and fill-finish surge capacity, not design, sets the real timeline
  • Antigen design for engineered or immune-evasive pathogens cannot be validated without the pathogen
  • Regulatory review, trial enrollment and global distribution dominate the schedule after the first dose exists

Who’s working on it

  • CEPI ↗Program

    Owns the 100 Days Mission target, ran an April 2026 Disease X platform call with awards up to 5 million dollars, and is seeking 2.5 billion for its 2027 to 2031 strategy

  • International Pandemic Preparedness SecretariatProgram

    Published its fourth annual 100 Days Mission implementation report in January 2026, finding encouraging progress but significant remaining work

  • ModernaCompany

    Went from published sequence to first-in-human dosing in about 65 days in 2020 and remains the reference implementation of a rapid mRNA platform

  • Kizzmekia Corbett-HelaireResearcher
    Harvard T.H. Chan School of Public Health

    Co-designed mRNA-1273 from sequence at the NIH Vaccine Research Center and now runs a coronavirus vaccine and therapeutic antibody design lab

  • University of OxfordAcademic lab

    Holds a CEPI award of up to 80 million dollars for rapid-response vaccine platform development, the main non-mRNA route to the 100-day target

  • BioNTechCompany

    The other mRNA platform proven at pandemic scale, now building regional manufacturing capacity, which is the real constraint on surge response

What to invest in

KindInvestmentScale
infrastructureStanding warm-base manufacturing capacity, distributed regionally, with pre-qualified fill-finish lines$$$$ > $1B
policyPre-agreed trial protocols, platform-technology regulatory pathways and allocation agreements that can be triggered on day one$$ $10M – $100M

Sci-fi concepts in reach

Engineered pandemic organismdirect

Sources